Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye

John Chen, S. E. Ebmeier, W. M. Sutherland, N. G. Ghazi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

PurposeTo assess ranibizumab (Lucentis) penetration into the retina after topical administration in a rabbit model.MethodsRanibizumab was topically applied to the right eye of rabbits according to three regimens: every 2 h (q2hr), four times daily (qid), and twice daily (bid). Intraocular penetration of ranibizumab was assessed at 3, 7, 14, 21, and 28 days following initiation of drops. At each time point, the anterior chambers, vitreous cavities, and blood of one of the rabbits from each subgroup were sampled for ranibizumab detection using enzyme-linked immunosorbent assay (ELISA), and both eyes were then enucleated for ranibizumab detection in the retina by confocal immunohistochemistry (CI). Another group of rabbits received intravitreal ranibizumab and was similarly sampled for comparison.ResultsCI showed ranibizumab staining in the right retina after 7 and 14 days of q2hr topical administration in two out of four experiments. No ranibizumab was detected in the left retina at any of the sampling time points. ELISA was positive in the vitreous of the right eye at 14 and 21 days in the q2hr treated rabbits in one out of four experiments. No ranibizumab was detected in the qid and bid subgroups. CI and ELISA of the aqueous and vitreous were consistently positive in the intravitreal group. Mild ranibizumab levels were detected in the blood in both the topical and intravitreal groups.ConclusionsTopically applied ranibizumab can be detected in the retina following high-frequency administration in a rabbit model. A trans-scleral route of penetration is suggested.

Original languageEnglish (US)
Pages (from-to)1504-1511
Number of pages8
JournalEye
Volume25
Issue number11
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Rabbits
Retina
Topical Administration
Enzyme-Linked Immunosorbent Assay
Ranibizumab
Immunohistochemistry
Anterior Chamber
Staining and Labeling

Keywords

  • confocal microscopy
  • ELISA
  • macular degeneration
  • rabbit
  • ranibizumab (Lucentis)
  • topical application

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Chen, J., Ebmeier, S. E., Sutherland, W. M., & Ghazi, N. G. (2011). Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. Eye, 25(11), 1504-1511. https://doi.org/10.1038/eye.2011.225

Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. / Chen, John; Ebmeier, S. E.; Sutherland, W. M.; Ghazi, N. G.

In: Eye, Vol. 25, No. 11, 01.01.2011, p. 1504-1511.

Research output: Contribution to journalArticle

Chen, J, Ebmeier, SE, Sutherland, WM & Ghazi, NG 2011, 'Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye', Eye, vol. 25, no. 11, pp. 1504-1511. https://doi.org/10.1038/eye.2011.225
Chen, John ; Ebmeier, S. E. ; Sutherland, W. M. ; Ghazi, N. G. / Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. In: Eye. 2011 ; Vol. 25, No. 11. pp. 1504-1511.
@article{5c29d7b2f3da41ca899ec5938e538573,
title = "Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye",
abstract = "PurposeTo assess ranibizumab (Lucentis) penetration into the retina after topical administration in a rabbit model.MethodsRanibizumab was topically applied to the right eye of rabbits according to three regimens: every 2 h (q2hr), four times daily (qid), and twice daily (bid). Intraocular penetration of ranibizumab was assessed at 3, 7, 14, 21, and 28 days following initiation of drops. At each time point, the anterior chambers, vitreous cavities, and blood of one of the rabbits from each subgroup were sampled for ranibizumab detection using enzyme-linked immunosorbent assay (ELISA), and both eyes were then enucleated for ranibizumab detection in the retina by confocal immunohistochemistry (CI). Another group of rabbits received intravitreal ranibizumab and was similarly sampled for comparison.ResultsCI showed ranibizumab staining in the right retina after 7 and 14 days of q2hr topical administration in two out of four experiments. No ranibizumab was detected in the left retina at any of the sampling time points. ELISA was positive in the vitreous of the right eye at 14 and 21 days in the q2hr treated rabbits in one out of four experiments. No ranibizumab was detected in the qid and bid subgroups. CI and ELISA of the aqueous and vitreous were consistently positive in the intravitreal group. Mild ranibizumab levels were detected in the blood in both the topical and intravitreal groups.ConclusionsTopically applied ranibizumab can be detected in the retina following high-frequency administration in a rabbit model. A trans-scleral route of penetration is suggested.",
keywords = "confocal microscopy, ELISA, macular degeneration, rabbit, ranibizumab (Lucentis), topical application",
author = "John Chen and Ebmeier, {S. E.} and Sutherland, {W. M.} and Ghazi, {N. G.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1038/eye.2011.225",
language = "English (US)",
volume = "25",
pages = "1504--1511",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye

AU - Chen, John

AU - Ebmeier, S. E.

AU - Sutherland, W. M.

AU - Ghazi, N. G.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - PurposeTo assess ranibizumab (Lucentis) penetration into the retina after topical administration in a rabbit model.MethodsRanibizumab was topically applied to the right eye of rabbits according to three regimens: every 2 h (q2hr), four times daily (qid), and twice daily (bid). Intraocular penetration of ranibizumab was assessed at 3, 7, 14, 21, and 28 days following initiation of drops. At each time point, the anterior chambers, vitreous cavities, and blood of one of the rabbits from each subgroup were sampled for ranibizumab detection using enzyme-linked immunosorbent assay (ELISA), and both eyes were then enucleated for ranibizumab detection in the retina by confocal immunohistochemistry (CI). Another group of rabbits received intravitreal ranibizumab and was similarly sampled for comparison.ResultsCI showed ranibizumab staining in the right retina after 7 and 14 days of q2hr topical administration in two out of four experiments. No ranibizumab was detected in the left retina at any of the sampling time points. ELISA was positive in the vitreous of the right eye at 14 and 21 days in the q2hr treated rabbits in one out of four experiments. No ranibizumab was detected in the qid and bid subgroups. CI and ELISA of the aqueous and vitreous were consistently positive in the intravitreal group. Mild ranibizumab levels were detected in the blood in both the topical and intravitreal groups.ConclusionsTopically applied ranibizumab can be detected in the retina following high-frequency administration in a rabbit model. A trans-scleral route of penetration is suggested.

AB - PurposeTo assess ranibizumab (Lucentis) penetration into the retina after topical administration in a rabbit model.MethodsRanibizumab was topically applied to the right eye of rabbits according to three regimens: every 2 h (q2hr), four times daily (qid), and twice daily (bid). Intraocular penetration of ranibizumab was assessed at 3, 7, 14, 21, and 28 days following initiation of drops. At each time point, the anterior chambers, vitreous cavities, and blood of one of the rabbits from each subgroup were sampled for ranibizumab detection using enzyme-linked immunosorbent assay (ELISA), and both eyes were then enucleated for ranibizumab detection in the retina by confocal immunohistochemistry (CI). Another group of rabbits received intravitreal ranibizumab and was similarly sampled for comparison.ResultsCI showed ranibizumab staining in the right retina after 7 and 14 days of q2hr topical administration in two out of four experiments. No ranibizumab was detected in the left retina at any of the sampling time points. ELISA was positive in the vitreous of the right eye at 14 and 21 days in the q2hr treated rabbits in one out of four experiments. No ranibizumab was detected in the qid and bid subgroups. CI and ELISA of the aqueous and vitreous were consistently positive in the intravitreal group. Mild ranibizumab levels were detected in the blood in both the topical and intravitreal groups.ConclusionsTopically applied ranibizumab can be detected in the retina following high-frequency administration in a rabbit model. A trans-scleral route of penetration is suggested.

KW - confocal microscopy

KW - ELISA

KW - macular degeneration

KW - rabbit

KW - ranibizumab (Lucentis)

KW - topical application

UR - http://www.scopus.com/inward/record.url?scp=80955136398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80955136398&partnerID=8YFLogxK

U2 - 10.1038/eye.2011.225

DO - 10.1038/eye.2011.225

M3 - Article

VL - 25

SP - 1504

EP - 1511

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

SN - 0950-222X

IS - 11

ER -